Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Correction: Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity

Fabien Staufferta, Jenny Serra-Vinardellb, Marta Gómez-Graub, Helen Michelakakisc, Irene Mavridouc, Daniel Grinbergb, Lluïsa Vilageliub, Josefina Casasd, Anne Bodlenner*a, Antonio Delgado*de and Philippe Compain*a
aLaboratoire de Synthèse Organique et Molécules Bioactives (SYBIO), Université de Strasbourg/CNRS (UMR 7509), Ecole Européenne de Chimie, Polymères et Matériaux (ECPM), 25 rue Becquerel, 67087 Strasbourg, France. E-mail: philippe.compain@unistra.fr; annebod@unistra.fr
bDepartament de Genètica, Microbiologia i Estadística, Universitat de Barcelona (UB), IBUB, IRSJD, CIBER de Enfermedades Raras (CIBERER), Av. Diagonal 645, E-08028, Barcelona, Spain
cDepartment of Enzymology and Cellular Function, Institute of Child Health, Athens, 11527, Greece
dResearch Unit on BioActive Molecules (RUBAM), Departament de Química Biomèdica, Institut de Química Avançada de Catalunya (IQAC-CSIC), Jordi Girona 18, 08034 Barcelona, Spain. E-mail: delgado@rubam.net
eUnit of Pharmaceutical Chemistry (Associated Unit to CSIC), Department of Pharmacology, Toxicology and Medicinal Chemistry, Faculty of Pharmacy, University of Barcelona (UB), Avga. Joan XXIII s/n, E-08028 Barcelona, Spain

Received 5th September 2017 , Accepted 5th September 2017

First published on 14th September 2017


Correction for ‘Stereodivergent synthesis of right- and left-handed iminoxylitol heterodimers and monomers. Study of their impact on β-glucocerebrosidase activity’ by Fabien Stauffert et al., Org. Biomol. Chem., 2017, 15, 3681–3705.


The authors regret that two references were omitted from the discussion concerning the heterodimeric concept and the role of the linker length in divalent inhibitors (pages 3682–3683).1,2 The additional references are given below.

In addition, since examples of divalent inhibitors based on enantiomeric iminosugar heads have been previously reported,1 the word ‘unprecedented’ should be deleted from the contents entry. The correct entry should read: “Janus-faced iminosugars act as pharmacological chaperones for the treatment of Gaucher disease.”

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

References

  1. Exploring the divalent effect in fucosidase inhibition with stereoisomeric pyrrolidine dimers: A. Hottin, D. W. Wright, E. Moreno-Clavijo, A. J. Moreno-Vargas, G. J. Davies and J.-B. Behr, Org. Biomol. Chem., 2016, 14, 4718 CAS.
  2. Expanding the library of divalent fucosidase inhibitors with polyamino and triazole-benzyl bridged bispyrrolidines: A. Hottin, S. Carrión-Jiménez, E. Moreno-Clavijo, A. J. Moreno-Vargas, A. T. Carmona, I. Robina and J.-B. Behr, Org. Biomol. Chem., 2016, 14, 3212 CAS.

This journal is © The Royal Society of Chemistry 2017